New painkiller with no apparent side effects or addictive qualities near to market

Jan 25, 2011

(PhysOrg.com) -- A powerful new painkiller, which was developed on the basis of the research conducted at Stony Brook University and with no apparent side effects or addictive qualities, may now be only a year or two from the consumer market.

"This offers a major paradigm shift in the control of pain," declares Dr. Simon Halegoua, Professor of Neurobiology & Behavior at Stony Brook who in the 1990s, teamed up with fellow Stony Brook professors Dr. Gail Mandel and Dr. Paul Brehm to identify a novel sodium ion channel involved in the transmission of pain. They predicted that a drug aimed at blocking this channel, PN1/Nav 1.7, would control pain. PN1 (Peripheral Neuron 1), is uniquely expressed in peripheral nerves such as those involved in pain transduction.

"When a patient is given an opiate like morphine, pain signals are still transmitted from sensory nerves to the central nervous system. Morphine action throughout the brain reduces and alters pain perception, but it also impairs judgement and results in drug dependence," explains Halegoua, also director of the Center for Nervous System Disorders at Stony Brook University. "With drugs targeting the PN1/Nav1.7 sodium ion channel, the pain signals would not be transmitted, even by the sensory nerves. And since the central is taken out of the equation, there would be no and no addictive qualities."

The potential for such drugs is enormous – the reduction or elimination of pain for patients with cancer, arthritis, migraine headaches, muscle pain, pain from burns, and from other debilitating diseases.

He notes that drugs in both oral and topical ointment forms, based on the research he conducted in a basement laboratory at Stony Brook with Mandel, a molecular biologist, and Brehm, an electrophysiologist, are currently in Phase II clinical trials in England and Canada.

The Research Foundation of the State University of New York is the holder of the various patents originating from the work of the Stony Brook researchers. Icagen Inc., now in partnership with Pfizer, holds the exclusive license to these patents and has announced their own drug has now entered Phase I clinical trials in the U.S.

Explore further: Hearing quality restored with bionic ear technology used for gene therapy

add to favorites email to friend print save as pdf

Related Stories

Study: Why cold is such a pain

Jun 14, 2007

German scientists have identified a key molecule that helps animals feel pain associated with low temperatures.

Scientist Unraveling Mystery of Treating Chronic Pain

Sep 14, 2009

(PhysOrg.com) -- Successfully treating chronic pain with opioids such as morphine -- minus the side effects -- may soon become a reality, bringing relief to millions of people who suffer from debilitating ...

Recommended for you

LED exposure is not harmful to human dermal fibroblasts

12 hours ago

There was a time when no one thought about light bulbs—one blew, you screwed another one in. Nowadays, it's more complicated, as energy efficiency concerns have given rise to a slew of options, including ...

User comments : 5

Adjust slider to filter visible comments by rank

Display comments: newest first

that_guy
3 / 5 (2) Jan 25, 2011
Tip of the hat to this guy for good medicinal research.
neiorah
5 / 5 (3) Jan 25, 2011
I wonder what blocking the sodium ion channel will do regarding other purposes they serve.
CarolinaScotsman
5 / 5 (1) Jan 25, 2011
Does the drug block other signals besides pain? If not, how does it discriminate between pain and say normal touch sensation. It it does block other signals, what dangers might that entail?
Caliban
2.7 / 5 (3) Jan 25, 2011
It was always my understanding that pain also served the purpose of stimulating the healing response in damaged areas.
So my question is- will this chemical, by entirely blocking pain impulse from the source to the brain, interfere with the healing process?
If so, then it would appear to only be useful in cases of palliative care for terminal illness.

I'm wondering if maybe there is some information missing here...

neilaconway
5 / 5 (1) Jan 26, 2011
Pain, or at least the reaction to it, serves to protect the body from further harm. Generalized suppression of any messages are certainly going to have unforeseen consequences. The system developed in partnership with some other system within the body; would this lead to an atrophy in the dependent system?

More news stories